Apimeds Pharmaceuticals US, Inc. (APUS) earnings date, results and what the price requires
NYSE · SEC CIK 0001894525 · SEC filings checked Oct 19, 2026
Next report
Nov 6, 2026
Estimated from reporting history (85-day cycle, SEC periodic report filing dates). Not confirmed.
Last close
$4.04
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$-11.96
Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 14, 2026 | — | $-20.2M | $-11.77 | Filing |
| Mar 31, 2026 | May 26, 2026 | — | $-35.1M | $-2.26 | Filing |
| Dec 31, 2025 | May 4, 2026 | — | $-1.2M | $2.21 | Filing |
| Sep 30, 2025 | Nov 12, 2025 | — | $-1.8M | $-0.14 | Filing |
| Jun 30, 2025 | Aug 19, 2025 | — | $-2.7M | $-2.57 | Filing |
| Mar 31, 2025 | May 20, 2025 | — | $-402,397 | $-0.05 | Filing |
| Dec 31, 2024 | Apr 15, 2025 | — | $-311,633 | $-0.04 | Filing |
| Sep 30, 2024 | — | — | $-332,521 | $-0.04 | — |
What would Apimeds Pharmaceuticals US, Inc. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.